Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Infinity Pharmaceuticals and MedImmune have said that the US Adopted Names Council, in consultation with the World Health Organization International Nonproprietary Names Expert Committee has approved the use of the nonproprietary or generic name retaspimycin for the companies' heat shock protein 90 inhibitor, IPI-504.
Subscribe to our email newsletter
Retaspimycin hydrochloride is currently being evaluated in clinical trials for the potential treatment of a variety of solid tumor cancers, including gastrointestinal stromal tumors, non-small cell lung cancer, and hormone resistant prostate cancer.